Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Public Health | Research article

The burden of type 2 diabetes pre-and during the COVID-19 pandemic – a review

Authors: Justine Sciberras, Lara Maria Camilleri, Sarah Cuschieri

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Introduction

Diabetes Mellitus is a chronic disease and a global epidemic. It is a known fact that co-morbidities, including Diabetes Mellitus, pose a higher risk of infection by COVID-19. Additionally, the outcomes following infection are far worse than in people without such co-morbities.
Factors contributing to the development of type 2 diabetes mellitus (T2DM) have long been established, yet this disease still bestows a substantial global burden. The aim was to provide a comprehensive review of the burden of diabetes pre-COVID-19 and the additional impact sustained by the diabetes population and healthcare systems during the COVID-19 pandemic, while providing recommendations of how this burden can be subsided.

Methodology

Literature searches were carried out on ‘Google Scholar’ and ‘PubMed’ to identify relevant articles for the scope of this review. Information was also collected from reliable sources such as the World Health Organisation and the International Diabetes Federation.

Results

T2DM presented with economic, social and health burdens prior to COVID-19 with an significant ‘Disability Adjusted Life Years’ impact. Whilst people with diabetes are more susceptible to COVID-19, enforcing lockdown regulations set by the Public Health department to reduce risk of infection brought about its own challenges to T2DM management. Through recommendations and adapting to new methods of management such as telehealth, these challenges and potential consequences of mismanagement are kept to a minimum whilst safeguarding the healthcare system.

Conclusion

By understanding the challenges and burdens faced by this population both evident pre-covid and during, targeted healthcare can be provided during the COVID-19 pandemic. Furthermore, implementation of targeted action plans and recommendations ensures the care provided is done in a safe and effective environment.
Appendix
Available only for authorised users
Literature
1.
Health P., “Diabetes: a National Public Health Priority - proposal for a National Strategy for diabetes,” Consult. Doc., 2015.
2.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018;14(2):88–98.PubMedCrossRef
3.
4.
International Diabetes Federation, “Global Fact Sheet 2019,” IDF Diabetes Atlas, no. 9th Edition, 2019.
5.
Hull R. L. Utzschneider K. M. Kahn S E, “Mechanisms linking obesity to insulinresistance and type 2 diabetes.,” Div. Metab. Endocrinol. Nutr. Dep. Med. VA Puget Sound Heal. Care Syst. Univ. Washington, 1660 South Columbian Way, Seattle, Washingt. 98108, USA., 2006.
6.
A. American et al., “Diagnosis and managment of the metabolic syndrome AHA / NHLBI Scientific Statement,” pp. 2735–2752, 2006.
7.
Cuschieri S. Type 2 diabetes – an unresolved disease across centuries contributing to a public health emergency. Diabetes Metab Syndr Clin Res Rev. 2019;13(1):450–3.CrossRef
8.
Pal R., Bhadada S. K., “COVID-19 and diabetes mellitus: An unholy interaction of two pandemics,” no. January, 2020.
9.
McGrath R, Al Snih S, Markides K, Hall O, Peterson M. The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years. BMC Geriatr. 2019;19(1):100.PubMedPubMedCentralCrossRef
10.
I. for H. M. and E. (IHME), “GBD compare data visualization,” IHME Website, 2020.
11.
Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. Lancet. 2017;389(10077):1431–41.PubMedCrossRef
12.
Kyu HH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859–922.CrossRef
13.
Roglic G., Global report on diabetes. World Health Organization, 2016.
14.
Fagg J, Valabhji J. How do we identify people at high risk of type 2 diabetes and help prevent the condition from developing? Diabet Med. 2019;36(3):316–25.PubMedCrossRef
15.
Riley L, Cowan M. World Health Organization noncommunicable diseases country profiles. Geneva: Switz. WHO Libr. Cat. Data; 2014.
16.
Wu H., Meng X., Wild S. H., Gasevic D., Jackson C. A., Socioeconomic status and prevalence of type 2 diabetes in mainland China, Hong Kong and Taiwan: a systematic review, J. Glob. Health, vol. 7, no. 1, 2017.
17.
Anjana RM, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585–96.PubMedCrossRef
18.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Metab. 2020;318(5):E736–41.
19.
Rajpal A., Rahimi L., Ismail-Beigi F., Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes, J. Diabetes, 2020.
20.
21.
Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–9.PubMedCrossRef
22.
Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280.e8.PubMedPubMedCentralCrossRef
23.
Wösten-Van Asperen RM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–27.PubMedCrossRef
24.
Yang JK, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–8.PubMedCrossRef
25.
Cuschieri S., Grech S., COVID-19 and diabetes: The why, the what and the how, J. Diabetes Complications, p. 107637, 2020.
26.
Ferrario CM, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10.PubMedCrossRef
27.
Amraei R, Rahimi N. COVID-19, renin-angiotensin system and endothelial dysfunction. Cells. 2020;9(7):1–18.CrossRef
28.
Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Curr Cardiol Rep. 2020;22(5):20–3.CrossRef
29.
Watkins J., Preventing a covid-19 pandemic, BMJ, vol. 368, no. February, pp. 1–2, 2020.
30.
Lei F, George K, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 8(April):e21, 20AD.
31.
Drucker DJ. Coronavirus infections and type 2 diabetes—shared pathways with therapeutic implications. Endocr. Rev. 2020;41(3):bnaa011.PubMedCrossRef
32.
Meng J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60.PubMedPubMedCentralCrossRef
33.
Mcmurray J. J. V, Pfeffer M. A., Ph D., Solomon S. D., “Spe ci a l R e p or t Renin – Angiotensin – Aldosterone System Inhibitors in Patients with Covid-19,” pp. 1653–1659, 2020.
34.
Pranata R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):983–90.CrossRef
35.
Lam K. W. et al., “Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome,” J. Infect. Dis., vol. 11794, 2020.
36.
Cuschieri S., “COVID-19 panic, solidarity and equity—the Malta exemplary experience,” J. Public Heal., no. May, 2020.
37.
Kipps C., Hamer M., Hill N., Lorgelly P., Enforced inactivity in the elderly and diabetes risk: initial estimates of the burden of an unintended consequence of COVID-19 lockdown, medRxiv, 2020.
38.
Sato Y, Nagasaki M, Kubota M, Uno T, Nakai N. Clinical aspects of physical exercise for diabetes/metabolic syndrome. Diabetes Res Clin Pract. 2007;77(3 SUPPL):87–91.CrossRef
39.
40.
Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo preventive trial with diet and exercise. Diabetologia. 1998;41(9):1010–6.PubMedCrossRef
41.
Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMed
42.
Park JH, Lee YE. Effects of exercise on glycemic control in type 2 diabetes mellitus in Koreans: the fifth Korea National Health and nutrition examination survey (KNHANES V). J Phys Ther Sci. 2015;27(11):3559–64.PubMedPubMedCentralCrossRef
43.
Nieman DC. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and Meta-analysis. Yearb Sport Med. 2012;2012:214–5.CrossRef
44.
W. H. Organization. Stay physically active during self-quarantine. Denmark: World Health Organization Copenhagen; 2020.
45.
Wicaksana A. L., Hertanti N. S., Ferdiana A., Pramono R. B., Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: a scoping review, Diabetes Metab. Syndr. Clin. Res. Rev., 2020.
46.
Pellegrini M, et al. Changes in weight and nutritional habits in adults with obesity during the ‘lockdown’ period caused by the COVID-19 virus emergency. Nutrients. 2020;12(7):1–11.CrossRef
47.
Ruiz-Roso MB, et al. Covid-19 confinement and changes of adolescent’s dietary trends in Italy, Spain, Chile, Colombia and Brazil. Nutrients. 2020;12(6):1–18.CrossRef
48.
Braekkan S, Siegerink B, Lijfering W, Hansen JB, Cannegieter S, Rosendaal F. Role of obesity in the etiology of deep vein thrombosis and pulmonary embolism: current epidemiological insights. Semin Thromb Hemost. 2013;39(5):533–40.PubMedCrossRef
49.
50.
Sattar N., McInnes I. B., McMurray J. J. V, Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms, Circulation, 2020.
51.
Kruglikov I. L., Scherer P. E., The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections, Obesity, 2020.
52.
Marelli S. et al., Impact of COVID-19 lockdown on sleep quality in university students and administration staff, J. Neurol., no. 0123456789, 2020.
53.
Banerjee M., Chakraborty S., Pal R., Diabetes self-management amid COVID-19 pandemic, Diabetes Metab. Syndr. Clin. Res. Rev., 2020.
54.
Ghosh A., Arora B., Gupta R., Anoop S., Misra A., Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in North India, Diabetes Metab. Syndr. Clin. Res. Rev., 2020.
55.
Wang C, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int. J. Environ. Res. Public Health. 2020;17(5):1729.PubMedCentralCrossRef
56.
National Diabetes Service Scheme, Managing worry about COVID-19 and diabetes, no. March, 2020.
57.
M. for Health and Malta, “Covid19 outbreak – Recommendations on self-care for people living with diabetes,” vol. 21, no. 1, pp. 1–9, 2020.
58.
Skinner T, Speight J. Supporting people with diabetes during a pandemic. Diabet Med. 2020;37(7):1155–6.PubMedCrossRef
59.
Hayes JF, Balantekin KN, Altman M, Wilfley DE, Taylor CB, Williams J. Sleep patterns and quality are associated with severity of obesity and weight-related behaviors in adolescents with overweight and obesity. Child Obes. 2018;14(1):11–7.PubMedPubMedCentralCrossRef
60.
Hasler G, et al. The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep. 2004;27(4):661–6.PubMedCrossRef
61.
Kryger M., Salamon E, Skomro RP, Ludwig S, Sleep complaints and restless legs syndrome in adult type 2 diabetics, vol. 2, no. 5, pp. 417–422, 2001.
62.
A. D. Association. Comprehensive medical evaluation and assessment of comorbidities. Diabetes Care. 2017;40(January):S25–32.CrossRef
63.
Singh SK, Jain R, Singh S. Vitamin D deficiency in patients with diabetes and COVID-19 infection: Diabetes Metab. Syndr. Clin. Res. Rev; 2020.
64.
Grant WB, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.PubMedCentralCrossRef
65.
Rondanelli M. et al., Self-Care for Common Colds: The Pivotal Role of Vitamin D, Vitamin C, Zinc, and Echinacea in Three Main Immune Interactive Clusters (Physical Barriers, Innate and Adaptive Immunity) Involved during an Episode of Common Colds - Practical Advice on Dosages , Evidence-based Complement. Altern. Med., vol. 2018, 2018.
66.
Xue T. et al., Blood glucose levels in elderly subjects with type 2 diabetes during COVID-19 outbreak: a retrospective study in a single center, Available SSRN 3566198, 2020.
67.
68.
Brown P. Type 2 diabetes risk identification and prevention: NICE public health guidance 38 in practice. Diabetes Prim. Care. 14(5):2012.
69.
Myers AK, et al. Perceptions of insulin pen use and technique in black and Hispanic/Latino patients with type 2 diabetes: a qualitative study. J Racial Ethn Heal Disparities. 2020:1–9.
70.
Peters AL, Garg SK. The silver lining to COVID-19: avoiding diabetic ketoacidosis admissions with telehealth. Diabetes Technol Ther. 2020;22(6):449–53.PubMedCrossRef
71.
Jones MS, Goley AL, Alexander BE, Keller SB, Caldwell MM, Buse JB. Inpatient transition to virtual care during COVID-19 pandemic. Diabetes Technol Ther. 2020;22(6):444–8.PubMedCrossRefPubMedCentral
72.
Joshi R., Atal S., Fatima Z., Balakrishnan S., Sharma S., Joshi A., Diabetes care during COVID-19 lockdown at a tertiary care centre in India, Diabetes Res. Clin. Pract., vol. 166, 2020.
73.
Wake D. J. et al., Endocrinology in the time of COVID-19: Remodelling Diabetes Services and Promoting Innovation, Eur. J. Endocrinol., vol. 1, no. aop, 2020.
74.
Zhai Y., Zhu W., Cai Y., Sun D., Zhao J., Clinical-and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis, Medicine (Baltimore)., vol. 93, no. 28, 2014.
75.
Misra A, Bloomgarden Z. Diabetes during the COVID-19 pandemic: a global call to reconnect with patients and emphasize lifestyle changes and optimise glycemic and blood pressure control: J. Diabetes; 2020.
76.
Anjana R. M. et al., “ACCEPTABILITY AND UTILISATION OF NEWER TECHNOLOGIES AND EFFECTS ON GLYCEMIC CONTROL IN TYPE 2 DIABETES–LESSONS LEARNT FROM LOCKDOWN,” Diabetes Technol. Ther., no. ja, 2020.
77.
Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19: advice from China. J Diabetes. 2020;12(5):417–9.PubMedCrossRef
78.
Bornstein S. R. et al., Practical recommendations for the management of diabetes in patients with COVID-19, lancet Diabetes Endocrinol., 2020.
79.
80.
Istituto Superiore di Sanità, “Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 29, 2020. COVID-19.,” 2020.
81.
Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area: Jama; 2020.
82.
Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi. 2020;41(2):145.
83.
Venema V., Coronavirus: should I worry about my lockdown eating?, BBC News, vol. 25, 2020.
84.
Slama S, et al. Care of non-communicable diseases in emergencies. Lancet. 2017;389(10066):326–30.PubMedCrossRef
85.
da Gama CAP, Guimarães DA, Cardoso CS, da Silva J, Oliveira CDL. Difficulties to treatment adherence according to the perception of people living with type 2 diabetes. Int J Health Sci (Qassim). 2019;7(2):29–37.
Metadata
Title
The burden of type 2 diabetes pre-and during the COVID-19 pandemic – a review
Authors
Justine Sciberras
Lara Maria Camilleri
Sarah Cuschieri
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00656-4

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue

Research article

Evaluation of biomarkers in liver following Solanum melongena green calyx administration in diabetic rats

Research article

The assessment of antidiabetic properties of novel synthetic curcumin analogues: α-amylase and α-glucosidase as the target enzymes

Review article

The mental health of healthcare workers in the COVID-19 pandemic: A systematic review

Research article

Relationship between guanosine triphosphate pathway and tetrahydrobiopterin in gestational diabetes mellitus

Research article

Diabetic retinopathy screening barriers among Palestinian primary health care patients: a qualitative study

Research article

Anti-inflammatory and antidiabetic effects of grape-derived stilbene concentrate in the experimental metabolic syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits